Download Free Medical Anti-diabetic Drugs PowerPoint Presentation

Anti-diabetic Drugs PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Pharmacology, which is titled "Anti-diabetic Drugs", to know about anti-diabetic drugs.

Tags : Pharmacology, Anti-diabetic Drugs

Published on : Jul 18, 2021 | Views : 4323 | Downloads : 23

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

ANTI-DIABETIC DRUGS Assoc. Prof. Iv. Lambev E-mail: itlambev@mail.bg www.medpharm-sofia.eu
Slide 2-

NORMOGLYCEMIA (WHO) Fasting glucose: 3.8-6.1 mmol/l HbA1C: 4.7–6.0% Glucose occupies a central position in metabolism as the predominant substrate for energy production.
Slide 3-

Suspected diabetes mellitus 75 g glucose p.o.: 2 h later
Slide 4-

ppt slide no 4 content not found
Slide 5-

HbA1C is a lab test that shows the average amount of sugar in blood over 2–3 months. It shows how well you are controlling DM. An HbA1C of 6% or less is normal. The following are the results when the HbA1C is being used to diagnose diabetes: Normal: Less than 5.7% Pre-diabetes: 5.7% to 6.4% DM: 6.5% or higher Values of HbA1C ≥ 7% are a signal for emergency change in treatment.
Slide 6-

ppt slide no 6 content not found
Slide 7-

Worldwide prevalence of diabetes mellitus
Slide 8-

Type 1 DM (beta-cell destruction) – about 10% of all patients. a) Autoimmune DM (the so called insulin-dependent DM – IDDM or juvenile-onset diabetes). It results from autoimmune mediated destruction of the beta cells of the pancreas. The rate of destruction is quite variable (and may reach 80% of the beta- cells of the Langerhans islets), being rapid in some individuals and slow in others. The rapidly progressive form is commonly observed in children, but also may occur in adults. The slowly progressive form generally occurs in adults and is sometimes referred to as latent autoimmune DM in adults (LADA). b) Idiopathic type 1 DM, which has no known etiology (has no evidence of autoimmunity). This form is more common among individuals of African and Asian origin. Patients periodically develop ketoacidosis. Diabetes mellitus (DM)
Slide 9-

Type 2 DM (predominantly insulin resistance with relative insulin deficiency or predominantly an insulin secretory defect with/without insulin resistance). DM of this type previously encompassed non- insulin-dependent diabetes (NIDDM), or adult-onset diabetes. It is a term used for individuals who have relative (rather than absolute) insulin deficiency. People with this type of diabetes (> 80% of patients with DM) frequently are resistant to the action of insulin. Other specific types of DM Genetic defects of beta-cell function (mutations on chromo- some 12 in a hepatic nuclear transcription factor referred to as HNF13. A second form is associated with mutations in the glucokinase gene on chromosome 7p.
Slide 10-

Genetic defects in insulin action (It is connected with some pediatric syndromes that have mutations in the insulin receptor gene with subsequent alterations in the insulin receptor function and extreme insulin resistance). Diseases of the exocrine pancreas (pancreatitis, trauma, cancer) Endocrinopathies (acromegaly, Cushing’s syndrome, glucagonoma, and pheochromocytoma). Drug- or chemical-induced (pentamidine, glucocorticoids, etc.). Viral infections may cause beta-cell destruction (e.g. mumps, adenovirus, cytomegalovirus, Coxsackie B, congenital rubella). Other genetic syndromes sometimes associated with DM (Down’s, Klinefelter’s and Turner’s syndromes, etc.). Gestational diabetes includes the former categories of gestational impaired glucose tolerance.
Slide 11-

> 520 000 patients with DM
Slide 12-

large blood vessel atherosclerosis coronary heart disease (CHD) limb ischaemia (diabetic foot!) stroke small blood vessel atherosclerosis retinopathy neuropathy nephropathy skin ulceration infection (mycoses, etc.) DM – complications:
Slide 13-

Diabetic retinopathy results in scattered haemorrhages, yellow exudates, and neovascularization Diabetic nephropathy
Slide 14-

Normoglycemia avoiding hypoglycemia or ketosis HbA1C < 6.5% (glycosylated hemoglobin) Reduce - nephropathy - neuropathy - retinopathy - infections (mycoses, etc) Management goals
Slide 15-

Glucometers
Slide 16-

Diet – weight control – low fat intake – normal protein intake – carbohydrates ~ 50% of total energy Control blood pressure (120/80 mm) BMI 18.5–24.9 Motor activity and compliance! !
Slide 17-

Insulin is a protein, secreted from the β-cells of the islets of Langerhans in the pancreas in response to a rise in blood glucose, and inhibited by a fall. t1/2: 5–6 min molecule mass: 5734 Da I. Insulin
Slide 18-

Glucagon Cortisol Adrenaline Somatotrophin (GH) hyper- glyce- mia Insulin Amylin hypoglycemia
Slide 19-

Amylin (Islet Amyloid Polypeptide – IAPP) reperesents a 37-residue peptide hormone. It is cosecreted with insulin from the pancreatic β-cells in the ratio of approximately 100:1. Amylin plays a role in glycemic regulation by slowing gastric emptying and promoting satiety, thereby preventing post-prandial spikes in blood glucose levels.
Slide 20-

Mechanism of action Insulin acts via receptors that are transmembrane glycoproteins. Each receptors has two binding sites. Receptor occupancy results in:
Slide 21-

1. Activation of insulin-dependent glucose transport processes in adipose tissue and muscle. 2. Inhibition of adenylyl cyclase- dependent processes (lipolysis, proteolysis, glycogenolysis).
Slide 22-

ATP cAMP 3’,5’-AMP Lipolysis in adipose tissue (hypercholesterolemia) AC PD (+) (-) Insulin
Slide 23-

4. Intracellular accumulation of potassium and phosphate (which are linked to glucose transport in some tissue). 5. Increased cellular amino acid uptake, DNA and RNA synthesis. 6. Increased oxidative phosphorylation.
Slide 24-

ppt slide no 24 content not found
Slide 25-

Insulin is extracted either from cattle or pig pancreas. Bovine (B) insulin differs from human insulin in three amino acid residues, and porcine (S) insulin in one, but their action is very similar to human. Nobel prize (1923)
Slide 26-

More recently, recombinant DNA technology has allowed in vitro manufacturing of insulin with the same structure as human (H) insulin. All current insulin preparations have a low content of impurities.
Slide 27-

Insulin is initially purified by protein extraction to form a crystalline product. It may then undergo either gel filtration to produce a single peak (SP) insulin or gel filtration and ion exchange chromatography which generates:
Slide 28-

monocomponent (MC), single component (SC) and rarely immunogenic (RI) insulin. Other abbreviations which are used for insulins are: Hum- and -man (for human ), PP (purified preparation)
Slide 29-

MAIN TYPES OF INSULIN PREPARATIONS Short-acting Intermediate-acting (they contain protamin or Zn) Long-acting (they contain both protamin & Zn) Injectors (with cartridge): OptiPen, OptiSet, Penfill, etc.
Slide 30-

Comparisons among insulins Type Onset of Peak Duration action activity Short- acting 10–20 min 1–2 h 5–7 h Interme- diate-act. 1–2 h 5–7 h 13–18 h Long-act. 2–4 h 8–14 h 18–36 h
Slide 31-

Insulins are used mainly in type 1 DM. Patients with type 2 DM use insulins in the following cases too: acute infections pregnancy surgical operations burn myocardial infarction ketoacidosis
Slide 32-

Therapy of DM with insulin is a replacement therapy. s.c.: 6 sec High compliance!
Slide 33-

s.c.
Slide 34-

Insulin pumps: They infuse subcutaneously fast-acting insulin through small catheter (very handy and very expensive).
Slide 35-

a) Insulins: Actrapid, Humulin R b) Analogues: Insulin aspart, Insulin lispro Short-acting insulins and analogues s.c. 15 min before meal 4 times daily chronobiologically (4:3:2:1)
Slide 36-

ppt slide no 36 content not found
Slide 37-

Ketoacidosis Short-acting insulin (i.v. or i.v. infusion) with physiological saline and potassium chloride
Slide 38-

Humulin M Humulin N Insulatard Mixtard 2. Intermediate-acting insulins and analogues s.c. 20 min before meal 2 times daily Chronobiologically
Slide 39-

3. Long-acting insulins s.c. 20 min before meal once daily Insulin detemir (Levemir) Insulin glargine (Lantus)
Slide 40-

Adverse effects of insulins hypoglycemia/coma allergic reactions insulin resistance lipodystrophia of subcutane- ous fat at or near injection local fibrosis
Slide 41-

II. Oral hypoglycemic and other drugs, used in DM type 2
Slide 42-

1. Biguanides: Metformin usually first line drug for type 2 DM reduces intestinal glucose absorption stimulates anaerobic glycolysis stimulates glucose uptake enhances insulin receptor binding
Slide 43-

excreted exclusively by the kidney does not increase weight and preferable in the obese GI side effects rarely lactic acidosis Metformin
Slide 44-

2. Sulfonylureas I generation: Chlorpropamide and Tolbutamide (Out) II generation: Glibenclamide (Maninil: tab. 5 mg) Gliclazide (Diaprel MR) Glipizide Gliquidone
Slide 45-

Unwanted effects Hypoglycemia, weight gain facial flushing following alcohol ingestion Mechanism of action promote enhanced insulin release from the pancreas leads to a reduction in hepatic glucose production
Slide 46-

displacement from protein binding sites – salicylates and sulphonamides interference with hepatic metabolism – inducers: rifampicin, phenytoin – inhibitors: cimetidine reduction of renal elimination – allopurinol, salicylates Sulfonylureas – important drug interactions:
Slide 47-

Inhibits intestinal alpha-glucosidase Decreases intestinal absorption of the mono- and polysaccharides. Produces flatulence and diarrhoea. - Acarbose (Gluco Bay): p.o. 4. Glucosidase inhibitors 3. Meglitinides: stimulate the release of insulin from pancreas by closing ATP-dependent potassium channels. - Nateglinide - Repaglinide
Slide 48-

5. Thiazolidinediones (TZDs) They increase tissue insulin sensitivity but have serious ADRs and the EMA recommended in Sept (2010) that they be suspended from the EU market: - Rosiglitazone (Avandia) has high cardiovascular risks. - Pioglitazone causes bladder tumors. - Troglitazone causes hepatitis.
Slide 49-

6. Glucagon-like peptide-1 (GLP-1) agonists (in type 2 DM): increase pancreatic secretion of insulin: Exenatide Bydureon (s.c./7 days): $323/4 doses, resp. $4200 per year
Slide 50-

Liraglutid Liraglutid is a GLP-1 agonist, which reduces, BM, HbA1C, and systolic blood pressure, and improves beta cell function of the pancreas (s.c. once a day)
Slide 51-

7. Inhibitors of Dipeptidil peptidase-4 (DPP-4): prevent degradation of incretin GLP-1 Sitagliptin (p.o.) Vildagliptin (p.o.)
Slide 52-

8. Inhibitors of reabsorption of glucose (SGLT2 inhibitors): p.o. Canagliflozin blocks in renal proximal tubule sodium / glucose co-transporter protein 2 (SGLT2), which re-absorbed 90% of the filtrated glucose. The result is increased glucosuria and plasma glucose levels are lowered. ADRs: Hypoglycaemia, vulvovaginal candidiasis urinary tract infections, polyuria, frequent urination.
Slide 53-

ppt slide no 53 content not found
Slide 54-

ppt slide no 54 content not found
Slide 55-

ppt slide no 55 content not found
Slide 56-

ppt slide no 56 content not found
Slide 57-

ppt slide no 57 content not found